Naratriptan Stada Hemofarm

Naratriptan, the active ingredient in Naratriptan Stada Hemofarm, is a Triptan presented as an oral dosage form for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Naratriptan Stada Hemofarm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is used to treat migraine-related pathways. - Migraine attack: provides rapid relief of headache pain and associated symptoms. - Migraine-associated nausea: helps reduce nausea that often accompanies an attack. - Migraine photophobia and phonophobia: improves tolerance to light and sound during an episode.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness after dosing. - Dry mouth: reduced salivation. - Paresthesia: tingling sensations in extremities. - Somnolence: occasional sleepiness.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia. - Severe hypertension: sudden rise in blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor when combined with serotonergic agents. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Ischemic stroke: rare cerebrovascular event. - Arrhythmia: irregular heart rhythm.

Before using Naratriptan, consider the following precautions. - Cardiovascular disease: avoid if you have coronary artery disease, angina, or history of myocardial infarction. - Uncontrolled hypertension: do not use if blood pressure is not well managed. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy: discuss risks with a healthcare professional; use only if benefits outweigh potential risks. - Breastfeeding: consult a physician before use, as drug may pass into milk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several drug classes. Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans or ergotamine derivatives: additive vasoconstrictive effects. - SSRIs, SNRIs, or other serotonergic agents: heightened serotonin toxicity. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma levels. - Cardiovascular stimulants: potential for excessive vasoconstriction. Moderate Interactions (Monitor Closely): - Antihypertensive agents: may require blood pressure monitoring. - Oral contraceptives: slight increase in migraine frequency in some users. - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy.